Dr. Mark Davis has confirmed that his wife's breast cancer has not returned. She continues to suffer from the damage that the chemo did (like hearing loss), but she is leading an active life.
IF YOU WISH TO SUPPORT DR. DAVIS' RESEARCH:
The California Institute of Technology (CalTech) is a 501 (c)(3) organization and has been qualified by the IRS to accept and receipt charitable contributions made to the Institute, its Labs and affiliates. Any gift should be made out to CalTech or the California Institute of Technology and in an accompanying memo specify that your gift is to be used to support Dr. Davis' research and laboratory. In the memo portion of the check also specify that the gift is to be used to support Dr. Davis' research and laboratory. Your contact if you have any questions is:
Joseph Boeke, Director of Development Operations, California Institute of Technology, 616-395-8001 (voice). Email: jrboeke@dar.caltech.edu. You should also check with your own tax advisor if you have any questions.
Current Status:
The drug is currently in Phase II trials for ovarian cancer, and the time to approval depends on how well the clinical trials proceed.
A second Phase II trial in lymphoma will begin shortly. Thus far, they have found that it works for a variety of tumors and they do not know at this time which tumors it works best in. They are very excited by the results they have observed thus far and are keeping their fingers crossed that in these murch larger clinical trials that they will see similar results.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment